{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:56:15Z","timestamp":1776448575718,"version":"3.51.2"},"reference-count":32,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,4,7]]},"DOI":"10.1136\/ejhpharm-2025-004927","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:20:12Z","timestamp":1776446412000},"page":"ejhpharm-2025-004927","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Y-site compatibility of co-administered continuous infusion solutions in intensive care units: preparatory study on physicochemical compatibility of 28 relevant medicinal products"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0326-7590","authenticated-orcid":false,"given":"Lutz","family":"Kreysing","sequence":"first","affiliation":[{"name":"Pharmacy, Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1433-0128","authenticated-orcid":false,"given":"Zoe","family":"Mittmann","sequence":"additional","affiliation":[{"name":"Pharmacy, Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Kraemer","sequence":"additional","affiliation":[{"name":"Pharmacy, Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2026041710200809000_ejhpharm-2025-004927v1.1","first-page":"44","article-title":"Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved","volume":"24","author":"Allen","year":"2020","journal-title":"Int J Pharm Compd"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.medin.2018.08.004","article-title":"Compatibility of drugs administered as Y-site infusion in intensive care units: A systematic review","volume":"44","author":"Castells Lao","year":"2020","journal-title":"Med Intensiva (Engl Ed)"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.22146\/ijp.2262","article-title":"Management of Y-Site Incompatibility of Intravenous Medication: A Systematic Review","volume":"2022","author":"Hanifah","year":"2022","journal-title":"Indonesian J Pharm"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.4","first-page":"528","article-title":"Inkompatibilit\u00e4ten-reduzierende Infusionsschemata f\u00fcr die Arzneimitteltherapie bei Intensivpatienten","volume":"62","author":"Mohr","year":"2021","journal-title":"An\u00e4sth Intensivmed"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-019-2618-z","article-title":"In-line filtration of intravenous infusion may reduce organ dysfunction of adult critical patients","volume":"23","author":"Schmitt","year":"2019","journal-title":"Crit Care"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00246-015-1157-x","article-title":"In-line Filtration Decreases Systemic Inflammatory Response Syndrome, Renal and Hematologic Dysfunction in Pediatric Cardiac Intensive Care Patients","volume":"36","author":"Sasse","year":"2015","journal-title":"Pediatr Cardiol"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.7","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082069","article-title":"Evaluation of Strategies for Reducing Vancomycin-Piperacillin\/Tazobactam Incompatibility","volume":"15","author":"Martin Mena","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-018-2602-6","article-title":"Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units","volume":"75","author":"Maison","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.9","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070471"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-021-03112-1","article-title":"Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review","volume":"77","author":"N\u00e9grier","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001723"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.12","unstructured":"Trissel's\u2122 2 Clinical Pharmaceutics Database (created by Lawrence A. Trissel). Available: https:\/\/online.lexi.com\/lco\/action\/ ivcompatibility\/trissels [Accessed 14 Dec 2025]."},{"key":"2026041710200809000_ejhpharm-2025-004927v1.13","unstructured":"King\u00ae guide to parenteral admixtures\u00ae. Available: https:\/\/www.kingguide.com [Accessed 14 Dec 2025]."},{"key":"2026041710200809000_ejhpharm-2025-004927v1.14","unstructured":"STABILIS\u00ae database. Available: https:\/\/stabilis.org\/ [Accessed 14 Dec 2025]."},{"key":"2026041710200809000_ejhpharm-2025-004927v1.15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00063-025-01264-x","article-title":"Empfehlungen zu Standardkonzentrationen f\u00fcr die kontinuierliche Infusion von Arzneimitteln auf Intensivstationen","volume":"120","author":"Kreysing","year":"2025","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.16","doi-asserted-by":"crossref","unstructured":"Meyn D , Hesener T , Kreysing L , et al . Entwicklung eines Infusionsschemas zur Vermeidung von Inkompatibilit\u00e4ten auf der Erwachsenenintensivstation. Med Klin Intensivmed Notfmed 2026. doi:10.1007\/s00063-025-01396-0","DOI":"10.1007\/s00063-025-01396-0"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.17","doi-asserted-by":"crossref","first-page":"20220002","DOI":"10.1515\/pthp-2022-0002","article-title":"Y-site compatibility of intravenous medications commonly used in intensive care units: laboratory tests on 75 mixtures involving nine main drugs","volume":"7","author":"Ayari","year":"2022","journal-title":"Pharm Technol Hosp Pharm"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010021","article-title":"Medication Safety in Intravenous Therapy: A Compatibility Study of Clonidine with Drugs Frequently Used in Intensive Care","volume":"13","author":"Koller","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.19","unstructured":"Council of Europe . European Directorate for the Quality of Medicines and Healthcare EPC. European Pharmacopoeia 11.7. 2025. Available: https:\/\/www.edqm.eu\/en\/d\/1778057"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2011.07.002"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.21","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/ajhp\/zxad132","article-title":"Stability and compatibility study guidelines for AJHP","volume":"80","author":"McPherson","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.22","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181e8adcc"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.23","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11040458","article-title":"Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.24","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2022-003577"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.25","doi-asserted-by":"crossref","first-page":"104043","DOI":"10.1016\/j.xphs.2025.104043","article-title":"Physicochemical compatibility of alprostadil injection with parenteral medications used in neonatal intensive care settings","volume":"115","author":"Hamilton","year":"2026","journal-title":"J Pharm Sci"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.26","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00431-020-03854-7","article-title":"Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units","volume":"180","author":"De Basagoiti","year":"2021","journal-title":"Eur J Pediatr"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2643-2647.2001"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.28","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001515"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.29","doi-asserted-by":"crossref","first-page":"104957","DOI":"10.1016\/j.ejps.2019.104957","article-title":"Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin\/tazobactam stability study","volume":"136","author":"Viola","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.30","first-page":"672","article-title":"Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection","volume":"51","author":"Trissel","year":"1994","journal-title":"Am J Hosp Pharm"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/scipharm88020025","article-title":"Medication Safety in Intravenous Therapy: A Compatibility Study and Analysis of Reaction Products of Dihydralazine and Metamizole","volume":"88","author":"Koller","year":"2020","journal-title":"Sci Pharm"},{"key":"2026041710200809000_ejhpharm-2025-004927v1.32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/j.2055-2335.2010.tb00515.x","article-title":"Stability of Intravenous Flucloxacillin Solutions used for Hospital\u2010in\u2010the\u2010Home","volume":"40","author":"To","year":"2010","journal-title":"Pharmacy Pract Res"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:20:26Z","timestamp":1776446426000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":32,"alternative-id":["10.1136\/ejhpharm-2025-004927"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004927","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}